Genzyme Targets Anchen Over Hectorol ANDA

Law360, New York (June 14, 2010, 1:27 PM EDT) -- Genzyme Corp. has filed a patent infringement suit against Anchen Pharmaceuticals Inc. in an effort to block a generic version of renal disease treatment Hectorol from being brought to market.

The complaint, filed Thursday in the U.S. District Court for the District of Delaware, came in response to an abbreviated new drug application Anchen filed in April seeking approval to manufacture generic Hectorol.

Hectorol, a treatment for end-stage renal disease, is covered by U.S. Patent Number 5,602,116, according to the suit. The patent was issued in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.